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Background: Australia and New Zealand have the highest incidence of colorectal cancer (CRC) in the world,
presenting considerable health, economic, and societal burden. Over a third of the Australian population live in
regional areas and research has shown they experience a range of health disadvantages that result in a higher
disease burden and lower life expectancy. The extent to which geographical disparities exist in CRC management
and outcomes has not been systematically explored. The present review aims to identify the nature of geographical
disparities in CRC survival, clinical management, and psychosocial outcomes.
Methods: The review followed PRISMA guidelines and searches were undertaken using seven databases covering
articles between 1 January 1990 and 20 April 2016 in an Australian setting. Inclusion criteria stipulated studies had
to be peer-reviewed, in English, reporting data from Australia on CRC patients and relevant to one of fourteen
questions examining geographical variations in a) survival outcomes, b) patient and cancer characteristics, c)
diagnostic and treatment characteristics and d) psychosocial and quality of life outcomes.
Results: Thirty-eight quantitative, two qualitative, and three mixed-methods studies met review criteria.
Twenty-seven studies were of high quality, sixteen studies were of moderate quality, and no studies were
found to be low quality. Individuals with CRC living in regional, rural, and remote areas of Australia showed poorer
survival and experienced less optimal clinical management. However, this effect is likely moderated by a range of
other factors (e.g., SES, age, gender) and did appear to vary linearly with increasing distance from metropolitan
centres. No studies examined differences in use of stoma, or support with stomas, by geographic location.
Conclusions: Overall, despite evidence of disparity in CRC survival and clinical management across geographic
locations, the evidence was limited and at times inconsistent. Further, access to treatment and services may not be
the main driver of disparities, with individual patient characteristics and type of region also playing an important role.
A better understanding of factors driving ongoing and significant geographical disparities in cancer related outcomes
is required to inform the development of effective interventions to improve the health and welfare of regional
Australians.
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Australia and New Zealand have the highest incidence
of colorectal cancer (CRC) in the world, with approxi-
mately 1 in 13 Australians likely to develop CRC in their
lifetime [1, 2]. CRC has the second-highest incidence of
all types of cancers in Australia, after prostate cancer
with an estimated 14,958 people diagnosed in 2012, and
with incidence rates expected to increase [1]. CRC is re-
sponsible for the second-highest burden of disease at-
tributable to cancer in Australia and in 2008–09,
accounted for the highest expenditure of any cancer
costing the Australian government $427 million in tan-
gible and intangible costs (e.g., screening programs, hos-
pital services, pharmaceuticals, etc., [3]). Thus, the
burden of CRC on the Australian health care system is
substantial and increasing.
Despite having one of the most urbanised populations
in the world (89.2%), over a third (approximately 8 mil-
lion) of Australians live in non-metropolitan locations
classified as regional, rural, or remote [4]. Regional Aus-
tralians face a range of health disadvantages that result in
greater disease burden and lower life expectancy [5, 6]. In
light of the high prevalence and disease burden of CRC
within Australia, geographic variation in CRC incidence,
management, and outcomes is an important question.
CRC can develop without early warning signs. If de-
tected early, CRC is very treatable as polyps can be re-
moved with a minimally invasive day procedure [7].
Therefore, early detection is essential to provide the best
treatment outcomes. In response to the proven effective-
ness of screening in reducing CRC mortality [8–10], the
Australian government introduced the National Bowel
Cancer Screening Program (NBCSP) in 2006. The pro-
gram involves mailing Australians aged >50 years an im-
munochemical Faecal Occult Blood Test (FOBT) kit.
Deaths from CRC in the United States have decreased
with the use of screening tools such as colonoscopies
and FOBTs [11]. However, in Australia, there remains a
relatively low rate of test completion with participation
rates appearing to be particularly low in remote and very
remote areas [12].
A number of social groups experience disadvantage in
cancer care in terms of preventative actions, access to rec-
ommended and timely treatment, psychosocial support,
and specialist care [12–15]. For example, Australians res-
iding in rural and remote areas may experience disadvan-
tage in cancer care relative to metropolitan residents;
while Indigenous Australians may be more likely to ex-
perience cancer care disadvantage relative to Caucasian
Australians. Clinical outcomes indicate that geographical
remoteness and Indigenous status may result in poorer
treatment and survival outcomes [16, 17]. Reasons for this
disadvantage are many and complex, and while cultural
barriers and a lack of access to services undoubtedly playa role, these are unlikely to be the only factors operating
to produce disparities. Additional patient, professional,
and system factors affect outcomes, although the relation-
ships between these are also likely to be complex. The
determination of the role of these factors is required to
ensure the best possible outcomes for patients. However,
no comprehensive synthesis of the available evidence has
been published.
The present review aimed to identify the nature of
geographical disparity in CRC survival, screening, treat-
ment, clinical management, and psychosocial outcomes.
An additional aim was to uncover broad trends in the
focus of published research addressing issues of geo-
graphical disparity relating to CRC in the Australian
context. We anticipate that by identifying patterns of co-
varying disparities across the domains reviewed, we may
be able to speculate about possible causes and make rec-
ommendations for future research to explore these.
Review questions
Questions to guide this review were developed by a Pro-
ject Steering Committee that included clinicians, re-
searchers, allied health practitioners, and stakeholder
representatives (Cancer Council Queensland). Research
questions were based on a preliminary scoping review of
CRC outcome research and formulated following the
PICO framework [18]. The 14 questions are reported in
Table 1 and can be grouped according to four themes 1.
Survival outcomes (1 question), 2. Patient and cancer
characteristics (2 questions), 3. Diagnostic and treatment
characteristics (7 questions) and 4. Psychosocial and
quality of life outcomes (4 questions).
Methods
The review methodology was planned and carried out
following the PRISMA statement for the conduct of sys-
tematic reviews [19]. The review protocol was registered
with PROSPERO; registration number CRD42016042666
(http://www.crd.york.ac.uk/PROSPERO/display_record.as-
p?ID=CRD42016042666). All stages of the methodology
from searching to extraction were carried out by two inde-
pendent reviewers and discrepancies were moderated by a
third independent reviewer. The results of the search and
the progression of articles through the screening stages is
presented in Fig. 1.
Search strategy
Searches were conducted in CINAHL, Medline, PsycInfo,
PubMed, Embase, ProQuest and Informit. The search cov-
ered all articles in these databases between January 1990
and the final search dates of 18th and 20th April 2016. In
addition to database searching, manual search methods
were also employed to identify potentially relevant articles.
This included reference list checks, and identifying key
Table 1 Clinical questions
Survival outcomes Q1. For individuals diagnosed with colorectal cancer, do those who reside in non-metropolitan areas have poorer
survival rates than those living in metropolitan areas in Australia?
Patient and cancer
characteristics
Q2. For individuals diagnosed with colorectal cancer, do non-metropolitan populations have different sociodemographic
characteristics compared with metropolitan populations in Australia?
Q3. For individuals diagnosed with colorectal cancer, do those living in non-metropolitan areas have a more advanced
stage of cancer at diagnosis compared with people living in metropolitan Australia?
Diagnostic and treatment
characteristics
Q4. For individuals who are in the colorectal cancer screening target group, are those residing in non-metropolitan
areas less likely to access screening services compared with people residing in metropolitan areas of Australia?
Q5. For individuals with colorectal cancer, are there differences in the clinical management of those who reside in
non-metropolitan areas and people residing in metropolitan areas of Australia?
Q6. Are individuals with colorectal cancer who live in non-metropolitan areas less likely to receive recommended clinical
management compared with those who live in metropolitan areas in Australia?
Q7. For individuals who have colorectal cancer, are those who live in non-metropolitan areas less likely to complete
prescribed treatment than those who live in metropolitan areas in Australia?
Q8. For individuals with colorectal cancer, are those in non-metropolitan areas more likely to experience delays in referral to,
and examination by, colorectal cancer specialist clinicians compared with those living in Australia’s metropolitan areas?
Q9. For individuals with colorectal cancer, are those in non-metropolitan areas less likely to participate in recommended
follow-up compared with those living in metropolitan areas in Australia?
Q10. Are patients with colorectal cancer who reside in non-metropolitan areas more likely to have stomas as part of
their treatment than patients residing in metropolitan areas?
Psychosocial outcomes and
quality of life
Q11. Do patients who reside in non-metropolitan areas have less support with stomas than patients who reside in
metropolitan areas, and does this impact on differences in quality of life?
Q12. In individuals with colorectal cancer, do those living in non-metropolitan areas have less access to psychosocial
care compared to those living in metropolitan areas of Australia?
Q13. For individuals with colorectal cancer, do those residing in non-metropolitan areas have poorer quality of life after
treatment compared with those in metropolitan areas in Australia?
Q14. For individuals with colorectal cancer, are those who reside in non-metropolitan areas more likely to experience
greater psychological distress than those who live in metropolitan areas in Australia?
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members of the Project Steering Committee.
Search terms were based on subject headings and key
words with separate queries designed for each individual
review questions. Search strings all comprised the key
terms of “colorectal cancer” or “colorectal neoplasm” or
“bowel cancer” or “colon cancer” or “rectal cancer” and
“Australia”. Terms relating to geographic disparities in-
cluded “geographic” or “metropolitan” or “urban” or
“rural” or “remote” or “regional”. Additional terms were
added for individual clinical questions, such as “sur-
vival”, “mortality”, “demographic”, “stage”, “tumour
grade”, “screening”, faecal occult”, “clinical manage-
ment”, “treatment”, “chemotherapy”, “radiotherapy”,
“guidelines”, “referral”, “treatment completion”, “follow-
up”, “stoma”, “colostomy”, “support”, “psychosocial sup-
port”, “quality of life”, and “psychological distress”. Syno-
nyms for these terms were also included in the search
strings, and searches were adjusted to best suit the
search characteristics of each database.
Eligibility criteria
Studies were included if they met the following criteria:
(1)the data being reported were from Australia;(2)the sample studied individuals with CRC or there
was a CRC specific sub-group included in the study;
(3)data were reported on outcome measures pertaining
to one of the clinical question under review; and
(4)data were presented on either:
(a)non-metropolitan versus metropolitan comparisons
or other geographical inequalities (e.g. low versus
high surgical caseload); or
(b)a qualitative study on geographical disparities; or
(c)a quantitative or qualitative study only for
non-metropolitan individuals; or
(d)an initiative or intervention designed to address
geographical differences in one or more of the
outcome measures after CRC diagnosis.
Studies were excluded if they were not available in
English, or were review articles, editorials, books, confer-
ence abstracts, or commentaries.
Screening
Screening followed a three-step process: duplicate
screening, title/abstract screening, and full-text screen-
ing. After removing duplicates, the titles and abstracts
were screened for relevance to one of the review ques-
tions. In cases where there was insufficient information
Fig. 1 Process of inclusion and exclusion of studies for the systematic review
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retained for full-text screening. Articles undergoing full-
text screening were checked against the eligibility cri-
teria outlined above.
Study quality
We utilised an assessment of study quality previously
developed for research in breast cancer [20]. This tool
was based on an existing valid and reliable tool, the
Newcastle-Ottawa Scale (NOS), which assesses the risk
of bias in non-randomised observational studies, includ-
ing case-control and cohort studies [21]; however an al-
ternate scoring system was utilised. Studies were scored
according to the extent that they met each of nine cri-
teria using an ordinal scale of 0 (high risk of bias), 1
(intermediate risk of bias), and 2 (low risk of bias). Cri-
teria scores are summed and categorised as “high” (14–
18), “moderate” (9–13) or “low” (<9) quality [20].
Qualitative studies were also assessed on nine pre-
determined criteria denoting risk of bias [22]. This tool
also comprised nine items and articles were graded using
the same procedure described above for quantitative ar-
ticles, with a total possible score out of 18. Mixed
methods studies were assessed for methodologicalquality as qualitative studies as this was the key focus of
the study results.
Additionally, we assessed the ‘Level of Evidence for
Quantitative Studies’ using published NHMRC criteria
[23] where level 1 evidence is considered the most scien-
tifically robust and valid. According to these criteria, a
case series, or cross-sectional study is Level IV and a
case-control study is Level III-3. A retrospective cohort
study is Level III-2 (aetiology) and an unselected or rep-
resentative case series is Level III-1. A prospective co-
hort study represents Level II evidence, while Level-I
studies are systematic reviews of Level-II studies.
Qualitative studies were likewise assessed on four
levels of evidence using published criteria [24]. These
levels are: Level I (generalizable studies with conceptual
frameworks), Level II (conceptual studies), Level III
(descriptive studies) and Level IV (single case studies).
Geographical classification systems
Several classificatory approaches have been used in the
studies reviewed and will be referred to when describing
the results of each study. A number of studies adopted
the simple distinction of metropolitan versus non-
metropolitan, whereby residents of major cities were
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More sophisticated approaches have also been adopted
that take into account the travelling distance to required
treatment centres. Other approaches include the use of a
number of formal geographical classifications of which
the most common are: the Australian Standard Geo-
graphic Classification (ASGC) Remoteness Areas; the
Rural, Remote and Metropolitan Areas (RRMA) Classifi-
cation; and the Accessibility/Remoteness Index of
Australia (ARIA).Results
From 1990 to 2016, and from an initial pool of 1448 in-
dependent articles, 43 published research articles were
reviewed. Although seven studies focused on a national
Australian population, the majority of studies were
state-specific, predominantly from South Australia (11),
Queensland (11), New South Wales (9), and Western
Australia (4), with one from Victoria. The study charac-
teristics of all 43 studies have been tabulated and pub-
lished in the Harvard Dataverse open source research
data repository [25]. These data can be accessed at
http://dx.doi.org/10.7910/DVN/8BTSUP.
Table 2 lists the studies reviewed (organised by the
question they provide data on), as well as the study qual-
ity ratings. Of the 43 studies included in this review, 38
were quantitative, two were qualitative, and three were
mixed methods designs. Data collection methods varied
greatly and consisted of population linkage data, survey
results, clinical records, focus groups, and interviews.
Seventeen of the studies used population-level data from
state or national cancer registries.
Twelve of the 43 studies were eligible to be included
in more than one of the review questions. There were
no eligible studies found that addressed question 10
(differences in use of stoma as treatment by residential
location), or question 11 (differences in support with
stomas by residential location). The following presenta-
tion of the results focuses on the broad trends for each
question.Study quality
The evidence reviewed was generally of high quality.
The quality scores and levels of evidence for all included
studies are shown in Table 2. Sixteen studies (37%) were
of moderate quality, while the majority (N = 27, 63%)
were high quality, and no studies were low quality.
Almost two thirds of quantitative studies were graded as
high quality with just over half of these classified as
Level II studies, 30% classified as Level III, and 12%
classified as Level IV. Two of the five included qualita-
tive and mixed-methods studies were of high quality and
all five provided Level III evidence.Survival outcomes
For survival outcomes (Q1), 11 of 17 included studies re-
ported significantly poorer survival from CRC for individ-
uals residing outside of metropolitan areas [26–31]. Most
of these studies were conducted in South Australia,
Queensland, or New South Wales, with limited data avail-
able at a national level. Studies that found differences in
survival or mortality rates between metropolitan and non-
metropolitan areas were all retrospective, population-level
studies using cancer registry data. Several studies using
ASGC and ARIA methods of geographical classification
[26, 27, 31–36] identified poorer survival rates in certain
non-metropolitan areas such as ‘inner regional’ or ‘moder-
ately accessible’ areas. Indeed, patients with CRC in ‘re-
mote’ or ‘very remote’ locations often demonstrated better
survival than other geographical areas.
Patient and cancer characteristics
Limited evidence emerged to suggest that patient sociode-
mographic characteristics (Q2) are implicated in geograph-
ical disparities. Of five reviewed studies, one investigated
gender [37], two investigated socioeconomic status (SES)
[37, 38], and two investigated Indigenous status [39, 40].
There were no studies found that investigated age.
No gender difference was observed in the one study
examining CRC incidence between metropolitan and
non-metropolitan areas (p = 0.693 males; p = 0.216 fe-
males) [37]. In terms of SES, the role that geographical
location plays is still unclear. There was some indication
that greater socioeconomic disadvantage was evident
amongst non-metropolitan patients with CRC (78%)
compared with metropolitan patients (36% disadvan-
taged) [38], though this is consistent with increased so-
cioeconomic disadvantage in non-metropolitan areas
more generally and may be unrelated to CRC [41]. Re-
garding Indigenous status, two studies [39, 40] included
in this review reported a lower incidence of CRC in Indi-
genous populations in discrete rural and remote areas,
compared to the national average (age-standardised inci-
dence rates of 20–40).
This review found a lack of evidence (only one of five
reviewed studies) to support differences in stage at diag-
nosis between patients with CRC from metropolitan and
non-metropolitan areas (Q3). Three of the five reviewed
studies found significant variations in stage at diagnosis
when examining colon and rectal cancer independently,
with colon cancer often diagnosed at a later stage than
rectal cancer, though this was irrespective of geograph-
ical location [42–44].
Diagnostic and treatment characteristics
Screening participation
Studies that focused on screening participation (Q4)
generally suggest that greater numbers of women and
Table 2 Studies included in the review including their quality scores and evidence level
Study Design Score Quality Level Question
AIHW (2007) [26] Quant 15 high II 1
AIHW (2014) [27] Quant 14 high II 1
Baade et al. (2011a) [28] Quant 16 high II 1
Chen et al. (2015) [31] Quant 15 high II 1
Coory et al. (2013) [32] Quant 16 high III-2 1
Cramb et al. (2012) [33] Quant 17 high II 1
Roder et al. (2015) [69] Quant 16 high II 1
Wilkinson & Cameron (2004) [35] Quant 9 moderate II 1
Coory, Ganguly & Thompson (2001) [39] Quant 15 high III-2 2
Cramb, Mengersen & Baade (2011) [37] Quant 13 moderate IV 2
Homewood, Coory & Dinh (2005) [40] Quant 15 high III-2 2
Baade et al. (2011b) [43] Quant 17 high III-2 3
AIHW (2015) [12] Quant 15 high II 4
Javanparast et al. (2010) [45] Quant 13 moderate IV 4
Martini et al. (2011) [47] Quant 16 high IV 4
Steffen et al. (2014) [70] Quant 15 high II 4
Tong, Del Mar & Kennedy (2000) [71] Quant 11 moderate IV 4
Varlow et al. (2014) [48] Quant 9 moderate IV 4
Ward et al. (2011) [72] Quant 16 high IV 4
Ward, Javanparest & Wilson (2011) [72] Qual 9 moderate III 4
Gilbar, Lee & Pokharel (2015) [50] Quant 11 moderate III-2 5
Armstrong et al. (2005) [53] Quant 11 moderate III-2 6
Armstrong et al. (2007) [54] Quant 11 moderate III-2 6
Young et al. (2007) [55] Quant 14 high II 6
Morris et al. (2007) [57] Quant 12 moderate III-2 7
Goldsbury et al. (2012) [60] Quant 15 moderate III-2 8
Emery et al. (2013) [58] Qual 17 high III 8
Pascoe et al. (2013) [59] Qual 15 high III 8
Ieropoli et al (2011) [63] Qual 11 moderate III 12
Dunn et al. (2013a) [15] Quant 16 high II 13
Dunn et al. (2013b) [64] Quant 14 high II 14
Baade et al. (2013) [29] Quant 17 high II 1, 2
Martin et al. (2015) [38] Quant 11 moderate III-3 1, 2
Beckmann et al. (2016) [30] Quant 16 high II 1, 3
Jong et al. (2004) [34] Quant 16 high II 1, 3
Yu et al. (2005) [44] Quant 16 high II 1, 3
Hall et al. (2005) [52] Quant 17 high II 1, 5
Hocking et al. (2014) [51] Quant 13 moderate II 1, 5
Singla et al. (2014) [36] Quant 14 high II 1, 5
Wichmann et al. (2013) [62] Quant 14 high III-2 1, 9
Armstrong et al. (2004) [42] Quant 11 moderate III-2 3, 6, 7
Veitch et al. (2008) [14] Qual 10 moderate III 4, 5, 8, 9, 12
Beckmann et al. (2014) [49] Quant 16 high III-2 5, 6
Note. Quant Quantitative, Qual Qualitative
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regardless of geographical location. Furthermore, signifi-
cantly lower screening participation was observed in
areas known to have large Indigenous populations and
populations with and low socioeconomic status [45].
However, no significant differences emerged in com-
parisons of metropolitan and non-metropolitan areas
generally or in barriers to screening. Five of the nine
studies investigated screening participation across a
range of geographic areas rather than collapsing into
metropolitan and non-metropolitan areas, with two
of these studies reporting higher rates of participa-
tion in inner regional or rural residents (eg. Martini
et al: 48.6%), whereas individuals in remote locations
had equivalent participation rates (46.0%) to metro-
politan residents (45.6%) [46, 47].
Knowledge about screening
Important geographical differences in knowledge about
bowel cancer screening were evident in one study [48].
The results showed a higher proportion of individuals in
metropolitan areas believing that screening is only ne-
cessary when experiencing symptoms (23.3% vs 16.6%
non-metropolitan).
Clinical management
Regarding clinical management (Q5 & 6), three studies
were identified that investigated geographic disparity in
chemotherapy [49–51], three studies focused on surgery
[36, 51, 52], one study focused on access to treatments
[14], and five studies investigated adherence to treat-
ment guidelines [42, 49, 53–55]. One noteworthy
omission was the lack of evidence with regards to radio-
therapy use in non-metropolitan areas. Only two studies
reported geographical differences for this question. For
example, Beckman and colleagues [49] reported that
chemotherapy was less likely to be received by rural pa-
tients with stage III colon cancer (Prevalence Ratio =
0.87), and Hocking and colleagues [51] found increased
use of combination chemotherapy in metropolitan pa-
tients (67.4% v 59.9%; p = 0.01).
Deviation from recommended clinical management
From five available studies, there was limited evidence to
conclude that deviation from recommended clinical
management occurred as a function of geographic loca-
tion (Q6). Generally, overall treatment received was con-
sistent with national guidelines and similar across
geographic locations, although one study reported over-
all discordance with clinical guidelines was more likely for
patients residing in rural areas (prevalence ratio 1.2) [42].
There was some evidence to suggest that rates of chemo-
therapy in patients with stage III CRC tended to be lower
in remote areas, as did preoperative examinations [42, 49].However, there was generally insufficient research avail-
able to address this question, and some of this evidence
(the NSW Colorectal Cancer Care Survey; [42, 53, 54] re-
lied on practitioner-self-report rather than archival records.
Further difficulties in determining geographic disparities
emerged as a result of most studies not reporting whether
rural and remote patients were receiving treatment in
regional centres or metropolitan centres, nor did they
examine the effect of this on outcomes. This may be par-
ticularly important given findings for Question 1 of more
favourable outcomes for patients from remote and very re-
mote regions who are required to travel for treatment.
Completion of treatment
Only two studies were found that investigated geograph-
ical differences in the completion of prescribed treat-
ment (Q7). Remote patients were less likely to complete
radiotherapy yet more likely to complete chemotherapy
treatment than patients in other areas [42]. This may be
due to access to radiotherapy facilities [56]. Treatment
completion was also shown to be poorer for patients
with greater area-based disadvantage (52.6% vs 76.1%),
measured using the Socio-Economic Indexes for Areas
(SEIFA; [57]). These studies did not report reasons for
these discrepancies.
Referral
There were only four studies that investigated geograph-
ical variation in referral delays (Q8), three of which did
not directly compare geographical locations [14, 58–60].
Diagnostic delays in cancer were found to generally be-
come more common with increasing rurality, due to an
undersupply of medical practitioners in these areas [61].
The reviewed studies highlight potential inadequacies in
the referral process for CRC patients in non-metropolitan
areas. However, none provided a direct comparison of re-
ferral times between CRC patients from different regions.
Alternative factors such as private health insurance status
and GP-specialist relationships were shown to impact on
referral times [59].
Follow-up
The sparse evidence (two studies) on participation in
recommended follow-up (Q9) suggests a willingness
from non-metropolitan patients to comply with recom-
mended follow-up and suggests that rates of follow-up
for these patients is high [14, 62]. Generally there is in-
sufficient data to draw definitive conclusions for this
question.
Use of stomas in treatment
The current review found no articles addressing ques-
tion 10 regarding geographical differences in patients’
receiving stomas as part of treatment.
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There were few studies focusing on psychosocial out-
comes and support of patients with CRC. For example,
no studies were found that addressed question 11 (geo-
graphical variation in support with stomas and the im-
pact on quality of life) of this review.
Reviewed studies provide limited evidence to deter-
mine whether there are geographical disparities in psy-
chological and social support, quality of life, and
psychological distress in patients with CRC. Only two
mixed-methods studies were found that investigated psy-
chosocial support received by non-metropolitan patients
with CRC (Q12). These studies suggest that rural pa-
tients typically looked to GPs and peers to meet their
support needs [14, 63]. There was, however, no direct
comparison to the support received by metropolitan pa-
tients. From the available evidence, we are unable to de-
termine the level of access or use of psychosocial care
services for patients with CRC generally, or across differ-
ent geographical regions.
Only a single study was located examining geographic
differences in quality of life for CRC patients (Q13). This
study found that remoteness of residence predicted
poorer outcomes in a cancer specific quality of life do-
main (OR = 0.42; no differences emerged on physical,
functional, social/family, and emotional well-being do-
mains) [15].
Only one study was located which examined patterns
of psychological distress in CRC survivors (Q14). This
study found that psychological distress at various time
points post treatment did not differ by geographic loca-
tion [64].
Discussion
This review found consistent evidence to suggest that is-
sues such as screening and early detection, socio-
demographic characteristics, tumour characteristics,
treatment options, and access to oncology services play
a complex role in shaping geographical disparities in sur-
vival. The majority of studies examining survival were
high quality, providing level II evidence. However, stud-
ies that were of only moderate quality were more likely
to report no significant difference in survival between
metropolitan and non-metropolitan CRC patients.
Some of the factors under review appeared to interact
with each other. For example, while SES is recognised as
a risk factor for reduced cancer survival, research sug-
gests that this may be due to treatment and healthcare
system factors (e.g. private versus public), as survival for
patients with CRC given equivalent treatment does not
appear to depend on SES [65, 66]. The reviewed evi-
dence also suggests that deviations from clinical man-
agement guidelines may be more likely to be influenced
by patient (age, gender, Indigenous status, and healthinsurance status) and system-level factors (access, centre
waitlists, and surgeon or hospital case-loading) than by
geographical location. Furthermore, regarding adherence
to prescribed treatment, patients may themselves choose
approaches that minimise disruptions to their lives (such
as moving to a larger town during treatment) and this is
likely to vary across patient and cancer characteristics.
Evidence for disparities in survival uncovered by this
review is consistent with trends for other types of cancer
in Australia [27]. Although somewhat inconsistent, the
evidence generally supports the assertion that survival is
poorer for patients with CRC in areas outside of major
cities, and is likely moderated by a range of contributing
factors.
We anticipated that the reviewed evidence would
highlight patterns of covarying disparities across differ-
ent factors and outcomes, and that this would shed light
on possible causes of these disparities. Unfortunately
there was insufficient evidence to achieve this. Across
this body of research, despite evidence of some geo-
graphical disparities, there was generally a lack of clear,
consistent findings on the nature of these disparities and
how they manifest for patients with CRC. The evidence
reviewed was inconsistent, or in some cases completely
lacking. The distribution of studies identified through
our search is displayed in Fig. 2. Geographical disparities
in psychosocial support, quality of life, and psychological
distress are not adequately addressed in the published
literature to date. Likewise, research into geographical
variations in adherence to prescribed treatment and rec-
ommended follow-up is also limited. Additionally, evi-
dence for geographical disparities in the use of stomas as
part of treatment, and the provision of support with
stomas, is non-existent.
The majority of published research has focused on
Question 1 and Question 4. Survival and screening have
to date been the topics of greatest interest to researchers
investigating the Australian context. These topics might
also have garnered the most attention due to the fact
that major data registries exist that store information re-
lating to survival and screening. Given difficulties in
collecting sufficient samples to draw meaningful com-
parisons across populations, it is no surprise that re-
searchers have tended towards addressing research
questions for which data already exists.
The challenge remains to identify data sources for the
under-researched issues identified by this review. There
may be opportunities to augment existing data collection
efforts that are underway to support the large state and
territory registries. For example, a short distress instru-
ment like the Distress Thermometer or K6 [67, 68]
could be routinely administered at the time information
is being recorded for the Australian state and territory
cancer registries. This would allow an examination of
Fig. 2 Distribution of studies for each clinical question
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individuals with different individual characteristics and
across geographical location of residence/treatment.
Despite the largest number of studies focusing on sur-
vival disparities, 35.3% (6/17) of these have grouped
non-metropolitan regions together for comparison with
metropolitan centres, and thus, should be considered
low in resolution. Evidence suggests this approach may
lack sensitivity for uncovering meaningful disparities be-
tween non-metropolitan regions. If, as the current evi-
dence highlights, it is inner regional areas that are at the
greatest disadvantage and that rural and remote areas
appear more similar to metropolitan centres (at least in
survival), then understanding these differences could po-
tentially shed light on currently unknown causes of dis-
parity. Furthermore, researchers run the risk of
concluding that no geographical disparity exists if all
non-metropolitan regions are collapsed together since
this will conceal important differences between metro-
politan centres and specific region-types. The state and
territory cancer registries record statistical local area and
patient postcode at diagnosis and therefore, we recom-
mend this data be used for more fine-grained analysis.
We recognise that the formulation of our review ques-
tions also targeted broad metropolitan versus non-
metropolitan discrepancies, though our analysis was able
to distinguish between region-types in cases where pri-
mary data at this level was reported. We recommend fu-
ture studies take a fine-grained approach to classifying
and analysing regional differences, or at minimumcollect detailed information regarding precise location of
residence and treatment received so that future analyses
are able to capture disparities more accurately. We ex-
pect that in coming years, more focused examination of
patient-, professional-, and system-level factors will allow
for the development of a more comprehensive frame-
work or instrument that can explain disparities based on
specific locations (e.g. postcode) rather than regions (e.g.
inner regional).
Limitations
The current review was limited by several factors. The
most notable being the absence of sufficient evidence to
address a number of the review questions. Our ability to
synthesise the available evidence was also limited by the
variation in design, methodology, samples, analysis, and
presentation of results of the included studies. However,
given the limited number of studies available in the area,
and the aim of this review to provide an overview of the
literature within each of the themes, it was important to
include all available evidence regardless of design.
Additionally, there was significant variation in the use of
geographic classification systems, which was further com-
plicated as some studies combined all non-metropolitan
locations into a single category while others analysed up
to five categories of remoteness.
Variations in study quality also prohibited clear con-
clusions. Factors that reduced quality scores in quantita-
tive studies were: not using a representative sample, not
adjusting for potential key confounders, inadequate or
Ireland et al. BMC Cancer  (2017) 17:95 Page 10 of 12unclear handling of missing data, and poor follow-up.
For qualitative studies, factors that reduced quality in-
cluded: not addressing interviewer bias, unclear data re-
cording methods, no rationale for sample size, and
inadequate description of sample.
Finally, the methodology of the review itself was lim-
ited in only reviewing published research. There may be
grey literature, theses, conference proceedings, or indus-
try reports that report data bearing on the questions
posed by this review.
Conclusions
This review found that patients with CRC in regional,
rural, and remote areas of Australia have a poorer sur-
vival rate and experience less optimal clinical manage-
ment; however, this evidence is limited and at times
inconsistent. Further, access to treatment and services
was not always the main driver of disparities, with indi-
vidual patient characteristics and type of region also
playing an important role. There is an urgent need for
more research to be conducted, particularly with respect
to rates of treatment completion, adherence to recom-
mended follow-up, experience of stomas, psychosocial
care, psychological distress and quality of life. This re-
view also highlights the need for geographical disparities
in the care of patients with CRC to be more thoroughly
analysed as the interrelationships between distance to
services, demographic factors, and patient outcomes are
evidently complex. The challenge for governments and
health service providers is to find a way in which best
practice in prevention, early diagnosis and ongoing man-
agement of CRC and associated psychosocial needs can
be made available in all non-metropolitan areas, and tar-
geted towards the specific needs of different metropol-
itan and regional populations.
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